All articles by Elisabeth Fisher

Speeding up European clinical trial regulation

When the European Commission announced the long-awaited revision of the European clinical trials regulation on 17 July 2012, it was…
Mobile revolution: how have drug developers embraced smart device technology?

As a conservative industry, Big Pharma is usually not an early adopter of new technologies. Recently, however, there have been…
Positive results for Lundbeck’s schizophrenia drug trial

Danish pharmaceutical company Lundbeck and its Japanese partner Otsuka have announced successful results from a Phase 3 clinical trial evaluating…
Plasma-based virus treatment: Q&A with Max-Planck-Institut’s Julia Zimmerman

When, in late 2011, news became public that researchers had found a way to block adenoviruses by using plasma to…
Curing addiction: vaccines to end drug abuse

The idea of vaccinating drug addicts against substance abuse is nothing new. In fact, researchers have been intrigued for nearly…

Diminishing vaccine wastage: next-gen of temperature-controlled packaging

The World Health Organisation (WHO) estimates the global vaccine wastage currently amounts to 50% for lyophilised and to 25% for…
UK Budget 2012: the pharmaceutical industry reacts

Association of the British Pharmaceutical Industry (ABPI) chief executive Stephen Whitehead:"The measures announced in the budget statement will help improve…
UK Budget 2012: boosting pharmaceutical research

Against the background of an economy struggling to recover from one of the deepest recessions in history, UK Chancellor George…
Track and trace: Europe’s battle against falsified drugs

With the approval of the Falsified Medicine Directive in February 2011, the European Union (EU) has finally made genuine steps…
Medical cargo theft: securing the supply chain

Once a clinical trial gets on track and patient recruitment has started, the main concern for drug firms is to…